CytomX Therapeutics (CTMX) Tops Q4 Earnings and Revenue Estimates
Portfolio Pulse from
CytomX Therapeutics (CTMX) reported Q4 earnings of $0.22 per share, surpassing the Zacks Consensus Estimate of a loss of $0.20 per share. This marks a significant improvement from the $0.01 per share earnings a year ago.
March 06, 2025 | 11:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CytomX Therapeutics reported Q4 earnings of $0.22 per share, significantly beating expectations and showing strong growth from the previous year.
The significant earnings beat and year-over-year growth are likely to positively impact CTMX's stock price in the short term as it indicates strong financial performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100